90 related articles for article (PubMed ID: 11458557)
1. New schizophrenia drug.
FDA Consum; 2001; 35(3):6. PubMed ID: 11458557
[No Abstract] [Full Text] [Related]
2. FDA panel OKs 3 antipsychotic drugs for pediatric use, cautions against overuse.
Kuehn BM
JAMA; 2009 Aug; 302(8):833-4. PubMed ID: 19706851
[No Abstract] [Full Text] [Related]
3. [Therapy of schizophrenia with high compliance. Ziprasidon increases pharmaceutical options].
Nervenarzt; 1999 Nov; 70(11 Suppl Ziprasidon):1-4. PubMed ID: 10603602
[No Abstract] [Full Text] [Related]
4. Ziprasidone (Geodon) for schizophrenia.
Med Lett Drugs Ther; 2001 Jun; 43(1106):51-2. PubMed ID: 11402259
[No Abstract] [Full Text] [Related]
5. Ziprasidone approved.
Hirsch M
Harv Ment Health Lett; 2001 Jun; 17(12):8. PubMed ID: 11439926
[No Abstract] [Full Text] [Related]
6. Combination of ziprasidone and clozapine in treatment-resistant schizophrenia.
Zink M; Mase E; Dressing H
Hum Psychopharmacol; 2004 Jun; 19(4):271-3. PubMed ID: 15181656
[TBL] [Abstract][Full Text] [Related]
7. Introduction. Ziprasidone in schizophrenia: from acute treatment to long-term management.
Kane JM
J Clin Psychiatry; 2003; 64 Suppl 19():3-5. PubMed ID: 14728083
[No Abstract] [Full Text] [Related]
8. [Exercising caution in choice of psychotropic drugs. Avoid drug-induced weight gain].
MMW Fortschr Med; 2002 May; Suppl 2():89. PubMed ID: 12070872
[No Abstract] [Full Text] [Related]
9. Focus on ziprasidone.
Green B
Curr Med Res Opin; 2001; 17(2):146-50. PubMed ID: 11759185
[TBL] [Abstract][Full Text] [Related]
10. Ziprasidone: a novel psychotropic with unique properties.
Ballas C; Yang C; O'Reardon J; Ballas P; Baldassano C
Expert Rev Neurother; 2004 Mar; 4(2):179-86. PubMed ID: 15853558
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the bioequivalence of generic versus branded clozapine.
Ereshefsky L; Glazer WM
J Clin Psychiatry; 2001; 62 Suppl 5():25-7. PubMed ID: 11305845
[No Abstract] [Full Text] [Related]
12. Ziprasidone-associated pedal edema in the treatment of schizophrenia.
Ku HL; Su TP; Chou YH
Prog Neuropsychopharmacol Biol Psychiatry; 2006 Jul; 30(5):963-4. PubMed ID: 16624468
[TBL] [Abstract][Full Text] [Related]
13. Patient- and facility-level factors associated with diffusion of a new antipsychotic in the VA health system.
Valenstein M; McCarthy JF; Ignacio RV; Dalack GW; Stavenger T; Blow FC
Psychiatr Serv; 2006 Jan; 57(1):70-6. PubMed ID: 16399965
[TBL] [Abstract][Full Text] [Related]
14. Prescribing behavior and marketing practices.
Stone AM
Psychiatr Serv; 2006 Mar; 57(3):419; author reply 419. PubMed ID: 16525009
[No Abstract] [Full Text] [Related]
15. Repeated acute dystonia following administration of amisulpride and ziprasidone in a patient with iron deficiency.
Chen HK; Chen CK; Tzeng NS
Prog Neuropsychopharmacol Biol Psychiatry; 2008 Aug; 32(6):1615-6. PubMed ID: 18597910
[No Abstract] [Full Text] [Related]
16. Changes in sexual function for outpatients with schizophrenia or other psychotic disorders treated with ziprasidone in clinical practice settings: a 3-month prospective, observational study.
Montejo AL; Rico-Villademoros F;
J Clin Psychopharmacol; 2008 Oct; 28(5):568-70. PubMed ID: 18794656
[No Abstract] [Full Text] [Related]
17. From the editor-in-chief's desk.
Koplewicz HS
J Child Adolesc Psychopharmacol; 2013 Oct; 23(8):515. PubMed ID: 24138008
[No Abstract] [Full Text] [Related]
18. Ziprasidone hydrochloride approved for treatment of schizophrenia, but with major warning.
Am J Health Syst Pharm; 2001 May; 58(9):758. PubMed ID: 11351914
[No Abstract] [Full Text] [Related]
19. Effective adjunctive use of tandospirone with perospirone for enhancing verbal memory and quality of life in schizophrenia.
Sumiyoshi T; Higuchi Y; Matsui M; Arai H; Takamiya C; Meltzer HY; Kurachi M
Prog Neuropsychopharmacol Biol Psychiatry; 2007 May; 31(4):965-7. PubMed ID: 17391821
[No Abstract] [Full Text] [Related]
20. A 6-month prospective, observational, naturalistic, uncontrolled study to evaluate the effectiveness and tolerability of oral ziprasidone in patients with schizophrenia.
Arango C; Gómez-Beneyto M; Brenlla J; Gastó C; Sarramea-Crespo F; Chamorro L; Masramon X; Díez T;
Eur Neuropsychopharmacol; 2007; 17(6-7):456-63. PubMed ID: 17234389
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
